Haichen Pharmaceutical Obtained the Drug Registration Approval for Rivaroxaban Tablet

Update: 30 October, 2023

Haichen Pharmaceutical obtained the drug registration approval for Rivaroxaban tablet, which is a novel oral anticoagulant with advantages such as rapid onset of action, predictable efficacy, low incidence of intracranial hemorrhage, and no need for routine coagulation monitoring and routine dosage adjustment.

---

File format: PDF

Size: -

MD5 Checksum: CAE55694421160C9723665CC71628627

Publication date: 30 October, 2023

Downloads: -

PDF Link: Haichen Pharmaceutical Obtained the Drug Registration Approval for Rivaroxaban Tablet PDF